Harding Loevner’s Neurocrine Biosciences NBIX Stock Holding History

Harding Loevner’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-767	Closed	-$81K	–	133
2022 Q3	$81K	Sell	767 -43	-5%	-$4.36K	﹤0.01%	90
2022 Q2	$79K	Hold	810	–	–	﹤0.01%	90
2022 Q1	$61K	Buy	810 +33	+4%	+$2.8K	﹤0.01%	95
2021 Q4	$66K	Buy	777 +215	+38%	+$19.8K	﹤0.01%	102
2021 Q3	$54K	Hold	562	–	–	﹤0.01%	99
2021 Q2	$55K	Hold	562	–	–	﹤0.01%	105
2021 Q1	$55K	Hold	562	–	–	﹤0.01%	110
2020 Q4	$54K	Hold	562	–	–	﹤0.01%	106
2020 Q3	$54K	Buy	562 +306	+120%	+$35.4K	﹤0.01%	137
2020 Q2	$31K	Hold	256	–	–	﹤0.01%	117
2020 Q1	$22K	Buy	+256	New	+$25.1K	﹤0.01%	121

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Harding Loevner's NBIX Position: Q4 2022 in Review

Harding Loevner sold out of Neurocrine Biosciences (NBIX) in Q4 2022, closing a stake of 767 shares — an estimated $81K sold.

Harding Loevner first reported a position in NBIX in Q1 2020 and held it in 11 quarters. The position peaked at $81K in Q3 2022. 529 funds tracked by Wall St. Rank hold NBIX as of Q4 2022.

Harding Loevner reported no remaining Neurocrine Biosciences position as of Q4 2022 after selling out during the quarter.
Harding Loevner sold 767 Neurocrine Biosciences shares in Q4 2022, an estimated $81K.
Harding Loevner first reported a position in Neurocrine Biosciences in Q1 2020 and held it in 11 quarters.
Harding Loevner's Neurocrine Biosciences position peaked at $81K in Q3 2022.
529 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2022.

Based on Harding Loevner's 13F filing for Q4 2022, filed 14 Feb 2023.